Amado J. Zurita-Saavedra, M.D.

Peer-Reviewed Articles

1. Wang E, Rupe ES, Mukhida SS, Johns AC, Campbell MT, Shah AY, Zurita AJ, Gao J, Goswami S, Jonasch E, Msaouel P, Tannir NM, Hahn AW. Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma. Eur Urol Focus None(None):None, 2024. PMID: 39307587.
2. Mateo J, Zurita AJ. 177 Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot. Lancet None(None):None, 2024. PMID: 39293463.
3. Triner D, Graf RP, Madison RW, Gjoerup O, Tukachinsky H, Ross JS, Quintanilha JCF, Li G, Cheng HH, Pritchard CC, Zurita AJ, Qin Q, Zhang T, Agarwal N, Reichert ZR, Mateo J, Cieslik M, Morgan TM. Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing. ESMO Open 9(9):103684, 2024. PMID: 39255537.
4. Venkatesh N, Tidwell RS, Yu Y, Aparicio A, Zurita AJ, Subudhi SK, Siddiqui BA, Mukhida SS, Gregg JR, Corn PG, Koutroumpakis E, McQuade JL, Frigo DE, Pilie PG, Huff C, Logothetis CJ, Hahn AW. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocr Relat Cancer None(None):None, 2024. PMID: 39324992.
5. Schmidt MJ, Naghdloo A, Prabakar RK, Kamal M, Cadaneanu R, Garraway IP, Lewis M, Aparicio A, Zurita-Saavedra A, Corn P, Kuhn P, Pienta KJ, Amend SR, Hicks J. Polyploid cancer cells reveal signatures of chemotherapy resistance. bioRxiv None(None):None, 2024. PMID: 39229204.
6. Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis None(None):None, 2024. PMID: 39019979.
7. Mallin MM, Rolle LTA, Schmidt MJ, Nair SP, Zurita AJ, Kuhn P, Hicks J, Pienta KJ, Amend SR. Cells in the Polyaneuploid Cancer Cell State are Pro-Metastatic. bioRxiv None(None):None, 2024. e-Pub 2024. PMID: 39071340.
8. Aparicio AM, Tidwell RSS, Yadav SS, Chen JS, Zhang M, Liu J, Guo S, Pilié PG, Yu Y, Song X, Vundavilli H, Jindal S, Zhu K, Viscuse PV, Lebenthal JM, Hahn AW, Soundararajan R, Corn PG, Zurita-Saavedra A, Subudhi SK, Zhang J, Wang W, Huff C, Troncoso P, Allison JP, Sharma P, Logothetis CJ. A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 30(13):2751-2763, 2024. e-Pub 2024. PMID: 38683200.
9. Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist 29(5):392-399, 2024. e-Pub 2023. PMID: 38035767.
10. Hahn AW, Kotecha RR, Viscuse PV, Pieretti AC, Wiele AJ, Jonasch E, Lee CH, Gao J, Zurita AJ, Shah AY, Campbell MT, Sharma P, Motzer RJ, Russo P, Wood CG, Tannir NM, Voss MH, Karam JA, Hakimi AA, Msaouel P. Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy. Eur Urol Focus None(None):None, 2023. e-Pub 2023. PMID: 36863962.
11. Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors. Am J Gastroenterol 118(9):1609-1617, 2023. e-Pub 2023. PMID: 37307533.
12. Wang K, Kumar T, Wang J, Minussi DC, Sei E, Li J, Tran TM, Thennavan A, Hu M, Casasent AK, Xiao Z, Bai S, Yang L, King LM, Shah V, Kristel P, van der Borden CL, Marks JR, Zhao Y, Zurita AJ, Aparicio A, Chapin B, Ye J, Zhang J, Gibbons DL, PRECISION Consortium GC, Sawyer E, Thompson AM, Futreal A, Hwang ES, Wesseling J, Lips EH, Navin NE. Archival single-cell genomics reveals persistent subclones during DCIS progression. Cell 186(18):3968-3982.e15, 2023. e-Pub 2023. PMID: 37586362.
13. Welter L, Zheng S, Setayesh SM, Morikado M, Agrawal A, Nevarez R, Naghdloo A, Pore M, Higa N, Kolatkar A, Thiele JA, Sharma P, Moore HCF, Richer JK, Elias A, Pienta KJ, Zurita AJ, Gross ME, Shishido SN, Hicks J, Velasco CR, Kuhn P. Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics. Cancers (Basel) 15(15):None, 2023. e-Pub 2023. PMID: 37568766.
14. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol 9(6):825-834, 2023. PMID: 37022702.
15. Karam JA, Msaouel P, Haymaker CL, Matin SF, Campbell MT, Zurita AJ, Shah AY, Wistuba II, Marmonti E, Duose DY, Parra ER, Soto LMS, Laberiano-Fernandez C, Lozano M, Abraham A, Hallin M, Chin CD, Olson P, Der-Torossian H, Yan X, Tannir NM, Wood CG. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. Nat Commun 14(1):2684, 2023. e-Pub 2023. PMID: 37164948.
16. Zurita AJ, Graf RP, Villacampa G, Raskina K, Sokol E, Jin D, Antonarakis ES, Li G, Huang RSP, Casanova-Salas I, Vivancos A, Carles J, Ross JS, Schrock AB, Oxnard GR, Mateo J. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. JCO Precis Oncol 6(None):e2200195, 2022. PMID: 35820087.
17. Chai S, Ruiz-Velasco C, Naghdloo A, Pore M, Singh M, Matsumoto N, Kolatkar A, Xu L, Shishido S, Aparicio A, Zurita AJ, Hicks J, Kuhn P. Identification of epithelial and mesenchymal circulating tumor cells in clonal lineage of an aggressive prostate cancer case. NPJ Precis Oncol 6(1):41, 2022. e-Pub 2022. PMID: 35729213.
18. De B, Venkatesan AM, Msaouel P, Ghia AJ, Li J, Yeboa DN, Nguyen QN, Bishop AJ, Jonasch E, Shah AY, Campbell MT, Wang J, Zurita-Saavedra AJ, Karam JA, Wood CG, Matin SF, Tannir NM, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU International 129(5):610-620, 2022. e-Pub 2021. PMID: 34228889.
19. De B, Venkatesan A, Msaouel P, Ghia A, Li J, Yeboa D, Nguyen Q, Bishop A, Jonasch E, Shah A, Campbell M, Wang J, Zurita-Saavedra A, Karam J, Wood C, Matin S, Tannir N, Tang C. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation. BJU International 129(5):None, 2022. PMID: None.
20. Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass 3(1):37-44, 2022. e-Pub 2021. PMID: 35475152.
21. Graf RP, Fisher V, Mateo J, Gjoerup OV, Madison RW, Raskina K, Tukachinsky H, Creeden J, Cunningham R, Huang RSP, Mata DA, Ross JS, Oxnard GR, Venstrom JM, Zurita AJ. Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. Eur Urol 81(1):37-47, 2022. e-Pub 2021. PMID: 34716049.
22. Chai S, Matsumoto N, Storgard R, Peng CC, Aparicio A, Ormseth B, Rappard K, Cunningham K, Kolatkar A, Nevarez R, Tu KH, Hsu CJ, Malihi P, Corn P, Zurita A, Hicks J, Kuhn P, Ruiz-Velasco C. Platelet-Coated Circulating Tumor Cells Are a Predictive Biomarker in Patients with Metastatic Castrate-Resistant Prostate Cancer. Mol Cancer Res 19(12):2036-2045, 2021. e-Pub 2021. PMID: 34462330.
23. Campbell MT, Matin SF, Tam AL, Sheth RA, Ahrar K, Tidwell RS, Rao P, Karam JA, Wood CG, Tannir NM, Jonasch E, Gao J, Zurita AJ, Shah AY, Jindal S, Duan F, Basu S, Chen H, Espejo AB, Allison JP, Yadav SS, Sharma P. Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. Nat Commun 12(1):6375, 2021. e-Pub 2021. PMID: 34737281.
24. Spetsieris N, Boukovala M, Alafis I, Davis J, Zurita A, Wang X, Tu SM, Chapin BF, Aparicio A, Corn P, Wang J, Subudhi SK, Araujo J, Papadopoulos J, Pruitt L, Weldon JA, Logothetis CJ, Efstathiou E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. Eur J Cancer 157(None):259-267, 2021. e-Pub 2021. PMID: 34536949.
25. Basu HS, Wilganowski N, Robertson S, Reuben JM, Cohen EN, Zurita A, Ramachandran S, Xiao LC, Titus M, Wilding G. Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities. Prostate 81(12):799-811, 2021. e-Pub 2021. PMID: 34170017.
26. Msaouel P, Oromendia C, Siefker-Radtke AO, Tannir NM, Subudhi SK, Gao J, Wang Y, Siddiqui BA, Shah AY, Aparicio AM, Campbell MT, Zurita AJ, Shaw LK, Lopez LP, McCord H, Chakraborty SN, Perales J, Lu C, Van Alstine ML, Elashoff M, Logothetis C. Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors. JAMA Netw Open 4(8):e2122998, 2021. e-Pub 2021. PMID: 34459906.
27. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7):None, 2021. PMID: 34326169.
28. Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Med 10(7):2341-2349, 2021. e-Pub 2021. PMID: 33650321.
29. Gerdtsson AS, Setayesh SM, Malihi PD, Ruiz C, Carlsson A, Nevarez R, Matsumoto N, Gerdtsson E, Zurita A, Logothetis C, Corn PG, Aparicio AM, Hicks J, Kuhn P. Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer. Cancers (Basel) 13(5):None, 2021. e-Pub 2021. PMID: 33801459.
30. Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 39(2):134.e9-134.e16, 2021. e-Pub 2020. PMID: 33187886.
31. Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 19(1):22-31.e5, 2021. e-Pub 2020. PMID: 32675015.
32. Bitar R, Szklaruk J, Martiniova L, Zurita AJ, Chery LJ, Ravizzini G. 18F-Fluciclovine Uptake in a Ureterocele. Clin Nucl Med 46(1):e3-e5, 2021. e-Pub 2020. PMID: 32956112.
33. Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol None(None):None, 2020. e-Pub 2019. PMID: 31272939.
34. Malihi PD, Graf RP, Rodriguez A, Ramesh N, Lee J, Sutton R, Jiles R, Ruiz Velasco C, Sei E, Kolatkar A, Logothetis C, Navin NE, Corn P, Aparicio AM, Dittamore R, Hicks J, Kuhn P, Zurita AJ. Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressive prostate cancer. Clin Cancer Res None(CCR-19-4100R1):None, 2020. e-Pub 2020. PMID: 32341031.
35. Ramesh N, Sei E, Tsai PC, Bai S, Zhao Y, Troncoso P, Corn PG, Logothetis C, Zurita AJ, Navin NE. Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing. Genome Biol 21(GBIO-D-20-00005R2):162, 2020. e-Pub 2020. PMID: 32631448.
36. Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM. Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist None(None):None, 2020. e-Pub 2019. PMID: 31501271.
37. Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clin Cancer Res 26(5):990-999, 2020. e-Pub 2020. PMID: 31941830.
38. Boukovala M, Spetsieris N, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wen S, Efstathiou E. A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. Eur J Cancer 127(None):67-75, 2020. e-Pub 2020. PMID: 31986451.
39. Syed S, Basourakos SP, Ali FS, Garcia JL, Zurita-Saavedra A, Gong Z. A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer. Am J Clin Oncol 43(2):87-93, 2020. e-Pub 2019. PMID: 31764016.
40. Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol None(None):None, 2019. e-Pub 2019. PMID: 31515154.
41. Efstathiou E, Davis JW, Pisters L, Li W, Wen S, McMullin RP, Gormley M, Ricci D, Titus M, Hoang A, Zurita AJ, Tran N, Peng W, Kheoh T, Molina A, Troncoso P, Logothetis CJ. Clinical and Biological Characterisation of Localised High-risk Prostate Cancer: Results of a Randomised Preoperative Study of a Luteinising Hormone-releasing Hormone Agonist with or Without Abiraterone Acetate plus Prednisone. Eur Urol 76(4):418-424, 2019. e-Pub 2019. PMID: 31176622.
42. Heath E, Heilbrun L, Mannuel H, Liu G, Lara P, Monk JP, Flaig T, Zurita A, Mack P, Vaishampayan U, Stella P, Smith D, Bolton S, Hussain A, Al-Janadi A, Silbiger D, Usman M, Ivy SP. Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer. Oncologist 24(9):1149-e807, 2019. e-Pub 2019. PMID: 31152080.
43. Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer 114(None):67-75, 2019. e-Pub 2019. PMID: 31075726.
44. Kim ST, Bittar M, Kim HJ, Neelapu SS, Zurita AJ, Nurieva R, Suarez-Almazor ME. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare. J Immunother Cancer 7(1):126, 2019. e-Pub 2019. PMID: 31088575.
45. Gerdtsson E, Pore M, Thiele JA, Gerdtsson AS, Malihi PD, Nevarez R, Kolatkar A, Velasco CR, Wix S, Singh M, Carlsson A, Zurita AJ, Logothetis C, Merchant AA, Hicks J, Kuhn P. Multiplex protein detection on circulating tumor cells from liquid biopsies using imaging mass cytometry. Converg Sci Phys Oncol 4(1):None, 2018. e-Pub 2018. PMID: 30906572.
46. Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol 80(3):583-589, 2017. e-Pub 2017. PMID: 28730293.
47. Zurita AJ, Gagnon RC, Liu Y, Tran HT, Figlin RA, Hutson TE, D'Amelio AM, Sternberg CN, Pandite LN, Heymach JV. Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma. Br J Cancer 117(4):478-484, 2017. e-Pub 2017. PMID: 28683470.
48. Msaouel P, Zurita AJ, Huang S, Jonasch E, Tannir NM. Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma. Oncotarget 8(26):42149-42158, 2017. e-Pub 2017. PMID: 28178674.
49. Kuhn P, Carlsson A, Luttgen MS, Dizon KK, Troncoso P, Corn P, Kolatkar A, Hicks JB, Logothetis C, Zurita AJ. Paired high-content analysis of prostate cancer cells in bone marrow and blood characterizes increased androgen receptor expression in tumor cell clusters. Clin Cancer Res 23(7):1722-1732, 2017. e-Pub 2016. PMID: 27702818.
50. Jonasch E, Hasanov E, Corn P, Moss T, Shaw K, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do K, Altamirano P, Zurita A, Doyle L, Lara P, Tannir NM. A Randomized Phase 2 Study of MK-2206 versus Everolimus in Refractory Renal Cell Carcinoma. Ann Oncol 28(4):804-808, 2017. e-Pub 2017. PMID: 28049139.
51. Subudhi SK, Aparicio A, Gao J, Zurita AJ, Araujo JC, Logothetis CJ, Tahir SA, Korivi BR, Slack RS, Vence L, Emerson RO, Yusko E, Vignali M, Robins HS, Sun J, Allison JP, Sharma P. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci U S A 113(42):11919-11924, 2016. e-Pub 2016. PMID: 27698113.
52. Dayyani F, Zurita AJ, Nogueras-González GM, Slack R, Millikan RE, Araujo JC, Gallick GE, Logothetis CJ, Corn PG. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer 16(None):721, 2016. e-Pub 2016. PMID: 27599544.
53. Cardó-Vila M, Marchiò S, Sato M, Staquicini FI, Smith TL, Bronk JK, Yin G, Zurita AJ, Sun M, Behrens C, Sidman RL, Lee JJ, Hong WK, Wistuba II, Arap W, Pasqualini R. Interleukin-11 Receptor Is a Candidate Target for Ligand-Directed Therapy in Lung Cancer: Analysis of Clinical Samples and BMTP-11 Preclinical Activity. Am J Pathol 186(8):2162-70, 2016. e-Pub 2016. PMID: 27317903.
54. McKay RR, Zurita AJ, Werner L, Bruce JY, Carducci MA, Stein MN, Heath EI, Hussain A, Tran HT, Sweeney CJ, Ross RW, Kantoff PW, Slovin SF, Taplin ME. A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy. J Clin Oncol 34(16):1913-20, 2016. e-Pub 2016. PMID: 27044933.
55. Williams SB, Davis JW, Wang X, Achim MF, Zurita-Saavedra A, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF. Neoadjuvant Systemic Therapy Before Radical Prostatectomy in High-Risk Prostate Cancer Does Not Increase Surgical Morbidity: Contemporary Results Using the Clavien System. Clin Genitourin Cancer 14(2):130-8, 2016. e-Pub 2015. PMID: 26558524.
56. Bilen MA, Zurita AJ, Ilias-Khan NA, Chen HC, Wang X, Kearney AY, Hodges S, Jonasch E, Huang S, Khakoo AY, Tannir NM. Hypertension and circulating cytokines and angiogenic factors in patients with advanced non-clear cell renal cell carcinoma treated with sunitinib: results from a phase II trial. Oncologist 20(10):1140-8, 2015. e-Pub 2015. PMID: 26306901.
57. Liu XD, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P, Tamboli P, Rao P, Karam JA, Wood C, Matin S, Zurita A, Bex A, Griffioen AW, Gao J, Sharma P, Tannir N, Sircar K, Jonasch E. Resistance to anti-angiogenic therapy is associated with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. Cancer Immunol Res 3(9):1017-29, 2015. e-Pub 2015. PMID: 26014097.
58. Zurita AJ, Pisters LL, Wang X, Troncoso P, Dieringer P, Ward JF, Davis JW, Pettaway CA, Logothetis CJ, Pagliaro LC. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis 18(3):276-80, 2015. e-Pub 2015. PMID: 26171883.
59. Karjalainen K, Jaalouk DE, Bueso-Ramos C, Bover L, Sun Y, Kuniyasu A, Driessen WH, Cardó-Vila M, Rietz C, Zurita AJ, O'Brien S, Kantarjian HM, Cortes JE, Calin GA, Koivunen E, Arap W, Pasqualini R. Targeting interleukin-11 receptor in leukemia and lymphoma: A functional ligand-directed study and hematopathology analysis of patient-derived specimens. Clin Cancer Res 21(13):3041-51, 2015. e-Pub 2015. PMID: 25779950.
60. Zurita AJ, Khajavi M, Wu HK, Tye L, Huang X, Kulke MH, Lenz HJ, Meropol NJ, Carley W, DePrimo SE, Lin E, Wang X, Harmon CS, Heymach JV. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advance neuroendocrine tumors. Br J Cancer 112(205 Suppl):1199, 2015. e-Pub 2015. PMID: 25756398.
61. Christianson DR, Dobroff AS, Proneth B, Zurita AJ, Salameh A, Dondossola E, Makino J, Bologa CG, Smith TL, Yao VJ, Calderone TL, O'Connell DJ, Oprea TI, Kataoka K, Cahill DJ, Gershenwald JE, Sidman RL, Arap W, Pasqualini R. Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. Proc Natl Acad Sci U S A 112(8):2521-6, 2015. e-Pub 2015. PMID: 25659743.
62. Kearney AY, Fan YH, Giri U, Saigal B, Gandhi V, Heymach JV, Zurita AJ. 8-chloroadenosine sensitivity in renal cell carcinoma is associated with AMPK activation and mTOR pathway inhibition. PLoS One 10(8):e0135962, 2015. e-Pub 2015. PMID: 26313261.
63. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. (Research highlights on this article published in Nature Reviews Urology on September 23, 2014 and Cancer Discovery on September 25, 2014). Sci Transl Med 6(252):252ra122, 2014. PMID: 25186177.
64. Mehran R, Nilsson M, Khajavi M, Du Z, Cascone T, Wu HK, Cortes A, Xu L, Zurita A, Schier R, Riedel B, El-Zein R, Heymach JV. Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. Cancer Res 74(10):2731-41, 2014. e-Pub 2014. PMID: 24626092.
65. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19(13):3621-30, 2013. e-Pub 2013. PMID: 23649003.
66. Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV, de Groot JF. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol 14(11):1379-92, 2012. e-Pub 2012. PMID: 22965162.
67. Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13(8):827-37, 2012. e-Pub 2012. PMID: 22759480.
68. Jonasch E, Futreal PA, Davis IJ, Bailey ST, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita AJ, Rini BI, Sharma P, Atkins MB, Walker CL, Rathmell WK. State of the science: an update on renal cell carcinoma. Mol Cancer Res 10(7):859-80, 2012. e-Pub 2012. PMID: 22638109.
69. Mateo J, Heymach JV, Zurita AJ. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Mol Diagn Ther 16(3):151-61, 2012. PMID: 22515658.
70. Hernandez-Yanez M, Heymach JV, Zurita AJ. Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep 14(3):221-9, 2012. PMID: 22434312.
71. Zurita AJ, George DJ, Shore ND, Liu G, Wilding G, Hutson TE, Kozloff M, Mathew P, Harmon CS, Wang SL, Chen I, Maneval EC, Logothetis CJ. Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol 23(3):688-94, 2012. e-Pub 2011. PMID: 21821830.
72. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23(1):46-52, 2012. e-Pub 2011. PMID: 21464158.
73. Gallick GE, Corn PG, Zurita AJ, Lin SH. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem 4(1):107-19, 2012. PMID: 22168167.
74. Bhatt RS, Zurita AJ, O'Neill A, Norden-Zfoni A, Zhang L, Wu HK, Wen PY, George D, Sukhatme VP, Atkins MB, Heymach JV. Increased mobilization of circulating endothelial progenitors in von hippel lindau disease and renal cell carcinoma. Br J Cancer 105(1):112-7, 2011. e-Pub 2011. PMID: 21673679.
75. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W, Pasqualini R. Targeting neuropilin-1 in human leukemia and lymphoma. Blood 117(3):920-7, 2011. e-Pub 2010. PMID: 21063027.
76. Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, Teh BT, Wood CG, Zurita AJ, King L. Innovations and challenges in renal cancer: summary statement from the third cambridge conference. Cancer 115(10 Suppl):2247-51, 2009. PMID: 19402064.
77. Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, Braidotti P, Wu HK, Zurita AJ, Saronni L, Cheng JB, Shalinsky DR, Heymach JV, Bertolini F. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 15(1):267-73, 2009. PMID: 19118054.
78. Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, Logothetis CJ, Lin SH. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res 6(8):1259-67, 2008. PMID: 18708358.
79. Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest 118(8):2697-710, 2008. PMID: 18618013.
80. Cardó-Vila M, Zurita AJ, Giordano RJ, Sun J, Rangel R, Guzman-Rojas L, Anobom CD, Valente AP, Almeida FC, Lahdenranta J, Kolonin MG, Arap W, Pasqualini R. A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11. PLoS One 3(10):e3452. doi:10.1371/journal.pone.0003452, 2008. e-Pub 2008. PMID: 18941632.
81. Kolonin MG, Bover L, Sun J, Zurita AJ, Do KA, Lahdenranta J, Cardó-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA, Souza GR, Staquicini FI, Kunyiasu A, Scudiero DA, Holbeck SL, Sausville EA, Arap W, Pasqualini R. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res 66(1):34-40, 2006. PMID: 16397212.
82. Chen L, Zurita AJ, Ardelt PU, Giordano RJ, Arap W, Pasqualini R. Design and validation of a bifunctional ligand display system for receptor targeting. Chem Biol 11(8):1081-91, 2004. PMID: 15324809.
83. Zurita AJ, Troncoso P, Cardó-Vila M, Logothetis CJ, Pasqualini R, Arap W. Combinatorial screenings in patients: the interleukin-11 receptor alpha as a candidate target in the progression of human prostate cancer. Cancer Res 64(2):435-9, 2004. PMID: 14744752.
84. Diestra JE, Condom E, Del Muro XG, Scheffer GL, Pérez J, Zurita AJ, Muñoz-Seguí J, Vigués F, Scheper RJ, Capellá G, Germà-Lluch JR, Izquierdo MA. Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications. J Urol 170(4 Pt 1):1383-87, 2003. PMID: 14501774.
85. Zurita AJ, Diestra JE, Condom E, García del Muro X, Scheffer GL, Scheper RJ, Pérez J, Germà-Lluch JR, Izquierdo MA. Lung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours. Br J Cancer 88(6):879-86, 2003. PMID: 12644825.

Invited Articles

1. Hernandez-Yanez M, Heymach JV, Zurita AJ. Circulating biomarkers in advanced renal cell carcinoma: clinical applications. Curr Oncol Rep 14(3):221-9, 2012. e-Pub 2012. PMID: 22434312.
2. Mateo J, Heymach JV, Zurita AJ. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Mol Diagn Ther 16(3):151-61, 2012. PMID: 22515658.
3. Zurita AJ, Arap W, Pasqualini R. Mapping tumor vascular diversity by screening phage display libraries. Journal Controlled Release 91(1-2):183-86, 2003. PMID: 12932650.

Other Articles

1. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7(1):37, 2023. PMID: 37072571.
2. Chahoud J, Msaouel P, Campbell MT, Bathala T, Xiao L, Gao J, Zurita AJ, Shah AY, Jonasch E, Sharma P, Tannir NM Nivolumab for the Treatment of Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): A Single-Institutional Experience and Literature Meta-Analysis. Oncologist 25(3):252-258, 2020. PMID: 32162795.
3. Gao J, He Q, Subudhi S, Aparicio A, Zurita-Saavedra A, Lee DH, Jimenez C, Suarez-Almazor M, Sharma P Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 34(43):5411-7, 2015. PMID: 25659583.
4. Zurita AJ, Jonasch E, Wu HK, Tran HT, Heymach JV Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 115(10 Suppl):2346-54, 2009. PMID: 19402074.
5. Ozawa MG, Zurita AJ, Dias-Neto E, Nunes DN, Sidman RL, Gelovani JG, Arap W, Pasqualini R Beyond receptor expression levels: the relevance of target accessibility in ligand-directed pharmacodelivery systems. Trends Cardiovasc Med 18(4):126-32, 2008. PMID: 18555185.
6. Salar A, Carratalà J, Zurita A, González-Barca E, Grañena A Bacteremia caused by CDC group IV c-2 in a patient with acute leukemia. Haematologica 83(7):670-72, 1998. PMID: 9718879.
7. Capdevila O, Zurita A, Domingo E, Corbella X, Alcaide F, Monfort JL, Fernández-Viladrich P Multiple cranial osteolytic lesions due to mycobacterium kansasii in a patient with AIDS. Scand J Infect Dis 30(3):305-6, 1998. PMID: 9790143.

Editorials

1. Zurita AJ. A second opportunity to come for anti-angiogenics in prostate cancer?. Transl Cancer Res 3(6):567-570, 2014. PMID: None.

Abstracts

1. Nordquist LT, Lengyelova E, Almaguel F, Mancini BR, Song H, Armstrong A, Zurita AJ, Anderson M, Parker M, Miller RM, Iagaru A. (TPS247)COMBAT: A study of 64Cu-SAR-BBN and 67Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer. 2024 ASCO Genitourinary Cancer Symposium None(None):None, 2024. PMID: None.
2. Zurita AJ, Danziger N, Scott TA, Gjoerup O, Zhong L, Tukachinsky H, Ross JS, Graf RP. Prognostic Value of Circulating Tumor DNA Fraction (TF) for Patients with Metastatic Renal Cell Carcinoma (mRCC). 2024 ASCO Genitourinary Cancer Symposium None(None):None, 2024. PMID: None.
3. Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Yepez Guevara E, Granwehr BP, Kaseb A, Naing A, Patel S, Shah AY, Skoulidis F, Tawbi HA, Wang L, Miller E, Zhang HC, Zurita-Saavedra A, Torres HA. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients with Solid Tumors. The Liver Meeting 2022 None(None):None, 2022. PMID: None.
4. Viscuse P, Tidwell R, Liu J, Guo S, Vundavilli H, Zhang M, Subudhi S, Zurita A, Corn P, Tu S, Araujo J, Wang J, Efstathiou E, Wang J, Pilié P, Troncoso P, Zhang J, Wang W, Logothetis C, Aparicio A. DynAMo: A dynamic allocation modular sequential trial of approved and promising therapies in men with metastatic CRPC. 2022 ASCO Annual Meeting None(None):None, 2022. PMID: None.
5. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Ming S, Jiang Y, Pant S, Shah AY, Zurita A, Tannir N, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1/2 inhibitor sapanisertib in combination with carboplatin plus paclitaxel in advanced solid malignancies and mTOR pathway alterations. AACR Annual Meeting 2022 None(None):None, 2022. PMID: None.
6. Hahn A, Wang X, Efstathiou E, Hwang H, Zurita A, Spetsieris N, Boukovala M, Wang J, Araujo J, Pilié P, Siddiqui B, Subudhi S, Corn P, Aparicio A, Tu S, Logothetis C. Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naïve prostate cancer (M0HNPC). None None(None):None, 2022. PMID: None.
7. Zurita A, Graf R, Villacampa G, Raskina K, Sokol E, Jin D, Huang R, Salas I, Carles J, Ross J, Schrock A, Oxnard G, Mateo J. Genomic evolution from hormonal therapies and suitability of prostate cancer diagnostic specimens for metastatic prostate cancer (mPC) genomic stratification. 2022 ASCO Genitourinary Cancer Symposium None(None):None, 2022. PMID: None.
8. Hahn AW, Tidwell R, Surasi DS, Pilie PG, Frigo D, Subudhi SK, Efstathiou E, Zurita AJ, Tu SM, Chapin BF, Fogelman DR, Starbuck MW, Corn PG, Aparicio A, McQuade JL, Logothetis C. Adiposity and response to androgen signaling inhibition (ASI) in men with metastatic castration-resistant prostate cancer (mCRPC). 2021 Genitourinary Cancers Symposium None(None):None, 2021. PMID: None.
9. Graf R, Fisher V, Gjoerup O, Schrock AB, Madison R, Morley S, Zhong L, Oxnard GR, Venstrom JM, Zurita AJ. Using real-world outcomes to evaluate the predictive power of tissue-assessed genomic biomarkers for taxane versus novel hormonal therapy (NHT) outcomes in metastatic castration-resistant prostate cancer (mCRPC). 2021 ASCO Annual Meeting None(None):None, 2021. PMID: None.
10. Msaouel P, Gao J, Yuan Y, Siefker-Radtke AO, Jonsach E, Goswami S, Zurita AJ, Campbell MT, Shah AY, Corn PG, Ramos C, Yan X, Chin C, Der-Torossian H, Tannir NM. Phase I/IB trial of sitravatinib (Sitra) + nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC) or other solid malignancies. 2021 Genitourinary Cancers Symposium None(None):None, 2021. PMID: None.
11. Karam JA Msaouel P, Matin SF, Campbell MT, Zurita AJ, Shah AY Wistuba II, Haymaker CL, Marmonti E, Douse DY, Parra ER, Solis LM, Laberiano C, Lozano M, Abraham A, Hallin M, Olson P, Der-Torossain H, Tannir NM, Wood CG. A phase II study of sitravatinib (Sitra) in combination with nivolumab (Nivo) in patients (Pts) undergoing nephrectomy for locally-advanced clear cell renal cell carcinoma (accRCC). 2021 Genitourinary Cancers Symposium None(None):None, 2021. PMID: None.
12. Graf R, Madison R, Gjoerup O, Zhong L, Morley S, Chopra S, Comment L, Fisher V, Li G, McGregor K, Schrock AB, Tukachinsky H, Snow T, Cho-Phan CD, Swaminathan A, Ross J, McCusker ME, Zurita AJ, Venstrom J. Real-world overall survival (OS) and time to therapy discontinuation (TTD) of patients (pts) with mCRPC treated with second-generation novel hormonal therapies (NHT) associated with tissue-based comprehensive genomic profiling (CGP). 2021 Genitourinary Cancers Symposium None(None):None, 2021. PMID: None.
13. Viscuse PV, Zhang M, Liu J, Tidwell R, Subudhi SK, Zurita AJ, Corn PG, Tu SM, Araujo JC, Wang J, Efstathiou E, Wang J, Pilie PG, Troncoso P, Zhang J, Logothetis C, Aparicio A. Outcomes in men with metastatic castrate-resistant prostate cancer treated with early platinum-based chemotherapy following an unsatisfactory response to androgen receptor (AR) inhibition as part of the phase II dynamic allocation modular sequential (DynAMo) trial. 2021 Genitourinary Cancers Symposium None(None):None, 2021. PMID: None.
14. Viscuse P, Zhang M, Liu J, Tidwell R, Subudhi S, Zurita A, Corn P, Tu S, Araujo J, Wang J, Efstathiou E, Wang J, Pilie P, Troncoso P, Zhang J, Logothetis C, Aparicio A. Linking the Aggressive Variant Prostate Cancer (AVPC) molecular signature (-ms) to androgen indifference in a prospective clinical trial. 2020 GU ASCO None(None):None, 2020. PMID: None.
15. Ramesh N, Sei E, Tsai P, Logothetis C, Corn P, Aparicio A, Zurita A, Navin N. Plasma genome sequencing identifies prostate cancer patients that are sensitive to platinum-based therapy. 2019 AACR None(None):None, 2019. PMID: None.
16. Malihi P, Graf R, Velasco C, Kolatkar A, Rodriguez A, Lee J, Sutton R, Corn P, Logothetis C, Aparicio A, Hicks J, Dittamore R, Zurita A, Kuhn P. Genomic instability as a marker of poor prognosis in advanced prostate cancer: Subclonal insights from whole-genome sequencing of single circulating tumor cells. 2019 AACR None(None):None, 2019. PMID: None.
17. Siddiqui B, Durand J, Gao J, Wang J, Aparicio A, Campbell M, Siefker-Radtke A, Tannir N, Corn P, Msaouel P, Shah A, Zurita A, Tu S, Suarez-Almazor M, Sudhakar T, Logothetis C, Sharma P, Subudhi S. Clinical and immunological analyses of immune checkpoint inhibitor-associated neuromuscular (NM) toxicities. 2019 ASCO None(None):None, 2019. PMID: None.
18. Shah AY, Kotecha R, Lemke E, Chandramohan A, Chaim J, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. 2019 GU ASCO None(None):None, 2019. PMID: None.
19. Laccetti A, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita A, Tannir N, Msaouel P, Shah A, Campbell M. Combination anti-angiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. 2019 GU ASCO None(None):None, 2019. PMID: None.
20. Ramesh N, Sei E, Gao R, Tsai P, Logothetis C, Zurita A, Navin N. Longitudinal monitoring of prostate cancer evolution by plasma genome sequencing. 2018 AACR None(None):None, 2018. PMID: None.
21. Zurita A, Ross J, Devine C, Chandramohan A, Wang X, Lim Z, Wang J, Corn P, Msaouel P, Tannir N. A randomized phase II trial of pazopanib (PAZ) vs. temsirolimus (TEM) in patients (pts) with advanced clear-cell renal cell carcinoma (accRCC) with intermediate or poor-risk disease (the TemPa trial). 2018 ASCO None(None):None, 2018. PMID: None.
22. Vaishampayan U, McDermott D, Matrana M, Rha S, Zurita A, Ho T, Keam B, Lee J, Joseph R, Ali S, Stadler W, Haas N, Sundararajan S, Park S, Mowat R, Picus J, Dudek A, Zakharia Y, Gan L, Atkins M. A phase 1/2 study evaluating the efficacy and safety of the oral CXCR4 inhibitor X4P-001 in combination with axitinib in patients with advanced renal cell carcinoma. 2018 ASCO None(None):None, 2018. PMID: None.
23. Efstathiou E, Wang X, Zurita A, Tu S, Aparicio A, Wang J, Corn P, Subudhi S, Araujo J, Reece L, Pruitt L, Vanalstine M, Logothetis C. A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent non metastatic hormone naïve prostate cancer (M0HNPC). 2018 ASCO None(None):None, 2018. PMID: None.
24. Chahoud J, Campbell M, Gao J, Zurita A, Shah A, Msaouel P, Ross J, Xiao L, Jonasch E, Sharma P, Tannir N. Nivolumab (nivo) for patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC): A single-institution experience. 2018 ASCO None(None):None, 2018. PMID: None.
25. Gao J, Karam J, Tannir N, Slack R, Ahrar K, Rao P, Ng C, Jonasch E, Campbell M, Matin S, Zurita A, Wang J, Blando J, Zhao H, Vence L, Basu S, Chen H, Allison J, Wood C, Sharma P. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy (CN), metastasectomy (MS) or post-treatment biopsy (Bx). 2018 ASCO None(None):None, 2018. PMID: None.
26. Shah A, Lemke E, Gao J, Chandramohan A, Campbell M, Zurita A, Xiao L, Wang J, Corn P, Jonasch E, Sharma P, Tannir N. Outcomes of patients (pts) with metastatic clear-cell renal cell carcinoma (mCCRCC) treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line (1L) immune checkpoint inhibitors (ICI). 2018 ASCO None(None):None, 2018. PMID: None.
27. Tannir N, Ross J, Devine C, Chandramohan A, Wang X, Lim Z, Wang J, Corn P, Zurita A. A randomized phase II trial of pazopanib (PAZ) versus temsirolimus (TEM) in patients (pts) with advanced clear-cell renal cell carcinoma (aCCRCC) of intermediate and poor-risk (the TemPa trial). 2018 ASCO None(None):None, 2018. PMID: None.
28. Zurita AJ, Carlsson A, Troncoso P, Hicks J, Logothetis CJ, Kuhn P. High-definition single cell analysis (HD-SCA) reveals enrichment in androgen receptor (AR) expression in tumor cell clusters in bone marrow and blood of metastatic castration-resistant prostate cancer (mCRPC) patients. None None(None):None, 2016. PMID: None.
29. Chapin BF, Mcguire SE, Wang X, Troncoso P, Davis JW, Navai N, Subudhi SK, Zurita AJ, Araujo JC, Pettaway CA, Matin SF, Pisters LL, Ward JF, Tu SM, Wang J, Le O, Logothetis C, Aparicio A. A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer. J Clin Oncol 33(None):None, 2015. PMID: None.
30. Efstathiou E, Li W, Gormley M, McMullin R, Sokol Ricci D, Davis JW, Li Ning Tapia EM, Troncoso P, Titus MA, Hoang A, Wen S, Zurita AJ, Tran N, Peng W, Kheoh T, Molina A, Logothetis C. Biological heterogeneity in localized high-risk prostate cancer (LHRPC) from a study of neoadjuvant abiraterone acetate plus leuprolide acetate (LHRHa) versus LHRHa. J Clin Oncol 33(None):None, 2015. PMID: None.
31. Corn PG, Tu SM, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Heath EI, Logothetis C, Aparicio A. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 33(None):None, 2015. PMID: None.
32. Bilen MA, Zurita AJ, Ilias-Khan NA, Chen HC, Wang X, Hodges S, Lim ZD, Jonasch E, Khakoo AY, Tannir NM. Circulating cytokines and angiogenic factors (CAFs) in patients with advanced non-clear cell renal cell carcinoma treated with sunitinib: Results from a phase II clinical trial. J Clin Oncol 33(7):None, 2015. PMID: None.
33. Williams SB, Davis JW, Achim MF, Zurita AJ, Matin SF, Pisters LL, Ward JF, Pettaway CA, Chapin BF. Effect of neoadjuvant systemic therapy prior to radical prostatectomy in high-risk prostate cancer on surgical morbidity: Contemporary results utilizing the Clavien System. J Clin Oncol 33(7):None, 2015. PMID: None.
34. Liu X, Hoang A, Zhou L, Kalra A, Yetil A, Sun M, Ding Z, Tamboli P, Rao P, Karam J, Wood C, Matin S, Zurita AJ, Bex A, Griffioen AW, Gao J, Sharma P, Tannir NM, Sircar K, Jonasch E. Association of resistance to antiangiogenic therapy with an immunosuppressive tumor microenvironment in metastatic renal cell carcinoma. J Clin Oncol 33(7):None, 2015. PMID: None.
35. Zurita AJ, Carlsson A, Luttgen MS, Bethel K, Logothetis C, Hicks J, Kuhn P. High-definition single cell analysis (HD-SCA) of prostate cancer (PCa) cells in matched bone marrow and blood from patients. ESMO 2014 Congress Abstract Book None(None):None, 2014. PMID: None.
36. Bilen MA, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin SH, Logothetis C, Tu SM. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 32(None):None, 2014. PMID: None.
37. Zurita AJ, Liu Y, Gagnon RC, D'Amelio A, Tran HT, Bartlett-Pandite AN, Heymach J. Osteopontin (OPN), TIMP-1, and interleukin (IL)-6 as prognostic (prog) for overall survival (OS) and independent from clinical criteria in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 32(None):None, 2014. PMID: None.
38. Zurita AJ, Pagliaro LC, Troncoso P, Davis JW. Presurgical axitinib and androgen deprivation therapy (ADT) in prostate cancer (PCa) patients (pts) presenting with lymph node (LN) metastasis. J Clin Oncol 32(None):None, 2014. PMID: None.
39. Corn PG, Tu S, Zurita AJ, Pagliaro LC, Logothetis C, Aparicio A. A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features. J Clin Oncol 32(None):None, 2014. PMID: None.
40. Yetil A, Barry ST, Heymach JV, Zurita AJ. Myeloid cell and plasma cytokine and angiogenic factor (CAF) dynamics in association with response to VEGF-receptor inhibitors cediranib and sunitinib. 2014 Annual AACR Meeting None(None):None, 2014. PMID: None.
41. Yetil A, Jonasch E, Wang X, Wood CG, Matin SF, Tran HT, Tannir NM, Heymach JV, Zurita AJ. Plasma cytokines and angiogenic factors associated with survival and clinical benefit from bevacizumab in a phase II presurgical study of metastatic renal cell carcinoma patients. 2013 Annual AACR Meeting (#4645) None(None):None, 2013. PMID: None.
42. Heath EI, Mannuel HD, Liu G, Lara P, Monk JP, Flaig TW, Zurita AJ, Vaishampayan UN, Stella PJ, Smith DW, Kobson K, Hussain A, Al-Janadi A, Ivy P, Heilbrun LK. Randomized phase II trial of docetaxel (Doc) and prednisone (Pred) with or without AZD2171 (cediranib), in chemotherapy-naive, metastatic castrate-resistant prostate cancer (mCRPC) (NCI 7451). J Clin Oncol 31(None):None, 2013. PMID: None.
43. Corn PG, Varkaris A, Li Ning Tapia EM, Araujo JC, Aparicio A, Tu SM, Zurita AJ, Efstathiou E, Qiao W, Wen S, Gallick GE, Logothetis C. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. J Clin Oncol 31(None):None, 2013. PMID: None.
44. Dayyani F, Nogueras-Gonzalez GM, Slack R, Millikan RE, Zurita AJ, Araujo JC, Gallick GE, Logothetis C, Corn PG. Serum insulin to predict time to castration-resistant progression and overall survival in metastatic androgen-dependent prostate cancer (mADPCa). J Clin Oncol 31(None):None, 2013. PMID: None.
45. Zurita AJ, Bischoff FZ, Gorlov I, Mayer JA, Pircher TJ, Mikolajczyk S, Logothetis C, Lin SH. Cadherin-11 (Cad11) for detection of epithelial-mesenchymal transition (EMT) in circulating prostate cancer (PCa) cells. J Clin Oncol 31(None):None, 2013. PMID: None.
46. Tran HT, Liu Y, Lin Y, Zurita Saavadra AJ, Baker-Neblett KL, Team VEG, investigators, Pandite LN, Heymach JV. Dynamic changes in plasma osteopontin as a markers of tumor response in metastatic renal cell carcinoma (RCC) patients treated with pazopanib. Ann Oncol 23(9):ix258-ix293, 2012. PMID: None.
47. Zurita-Saavedra A, Liu Y, Lin Y, Tran HT, Team VEG, investigators, Pandite LN, Heymach JV. Multivariate analysis of cytokines and angiogenic factors (CAFS) and established prognostic parameters in metastatic renal cell carcinoma (mRCC) patients (PTS) receiving pazopanib or placebo. Ann Oncol 23(9):ix261, 2012. PMID: None.
48. Efstathiou E, Davis JW, Troncoso P, Titus MA, Hoang A, Wen S, Zurita AJ, Tran N, Molina A, Logothetis C. Cytoreduction and androgen signaling modulation by abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus LHRHa in localized high-risk prostate cancer (PCa): Preliminary results of a randomized preoperative study. J Clin Oncol 30(None):None, 2012. PMID: None.
49. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuiyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W, Pasqualini R. Therapeutic targeting of leukemia and lymphoma with a neuropilin-1 binding pro-apoptotic peptide. 2012 Annual AACR Meeting (#2903) None(None):None, 2012. PMID: None.
50. Nieto Y, Tannir NM, Tu S, Jones RB, Zurita AJ, Aparicio A, Bassett R, Margolin KA, Holmberg L, Champlin RE, Pagliaro LC. Phase II trial of vevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT). J Clin Oncol 30(None):None, 2012. PMID: None.
51. Zurita AJ, Khajavi M, Wang X, Wood CG, Matin SF, Fiorentino S, McKee KS, Tran HT, Heymach J, Jonasch E. Plasma cytokines and angiogenic factors (CAFs) associated with risk of recurrence and tumor dependence in patients (pts) with nonmetastatic renal cell carcinoma (RCC). J Clin Oncol 30(None):None, 2012. PMID: None.
52. Aparicio A, Harzstark AL, Lin E, Corn PC, Araujo JC, Tu S, Pagliaro LC, Millikan RE, Arap W, Kim J, Ryan CJ, Zurita AJ, Tannir NM, Lin AM, Small J, Mathew P, Jones DM, Troncoso P, Thall PF, Logothetis C. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol 29(None):None, 2011. PMID: None.
53. Liu Y, Tran HT, Lin Y, Martin A, Zurita AJ, Sternberg CN, Amado RG, Pandite LN, Heymach J. Plasma cytokine and angiogenic factors (CAFs) predictive of clinical benefit and prognosis in patients (Pts) with advanced or metastatic renal cell cancer (mCRR) treated in phase III trials of pazopanib (PAZO). J Clin Oncol 29(None):None, 2011. PMID: None.
54. Zurita AJ, Ward JF, Araujo JC, Pettaway CA, Dieringer P, Wang X, Troncoso P, Logothetis C. Neoadjuvant trial of sunitinib malate and androgen ablation (ADT) in patients with localized prostate cancer (PCa) at high risk for recurrence. J Clin Oncol 29(None):None, 2011. PMID: None.
55. Zurita AJ, Heymach J, Khajavi M, Tye L, Huang X, Kulke M, Lenz H, Meropol NJ, Carley W, DePrimo SE, Harmon CS. Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 29(None):None, 2011. PMID: None.
56. George DJ, Halabi S, Zurita AJ, Creel P, Mundy K, Turnbull JD, Yenser Wood SE, Armstrong AJ, Varley RJ, Madden J, Moul JW. Investigator -initiated pilot study of sunitinib malate in patients with newly diagnosed prostate cancer prior to prostatectomy: A trial of the DoD/PCF prostate cancer clinical trials consortium. J Clin Oncol 29(None):None, 2011. PMID: None.
57. Liu Y, Tran T, Lin Y, Martin A, Zurita A, Sternberg CN, Amado RG, Pandite LN, Heymach J. Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC). J Clin Oncol 29(None):None, 2011. PMID: None.
58. Zurita AJ, Khajavi M, Mulders P, Yan S, McKee KS, Tran HT, Pike L, Mookerjee B, Jurgensmeier J, Heymach J. Cytokine and angiogenic factor (CAF) profiling for identification of markers associated with response to cediranib in metastatic renal cell carcinoma (mRCC). J Clin Oncol 29(None):None, 2011. PMID: None.
59. Pagliaro LC, Zurita AJ, Araujo JC, Ward JF, Davis JW, Pettaway CA, Tu S, Kim J, Dieringer P, Logothetis C, Pister LL. Presurgical docetaxel (Doc) and androgen deprivation therapy (ADT) in lymph node-positive prostate cancer (PCa). J Clin Oncol 29(None):None, 2011. PMID: None.
60. Tran HT, Liu Y, Lin Y, Martin A, Baker KL, Fritsche HA, Zurita AJ, Pandite L, Heymach J. Use of a multiplatform analysis of plasma cytokines and angiogenic factors (CAFs) to identify baseline CAFs associated with pazopanib response and tumor burden in renal cell carcinoma (RCC) patients. J Clin Oncol 28(15S):None, 2010. PMID: None.
61. Zurita AJ, Khajavi M, Logothetis CJ, Lin SH. Clinical applications for osteoblast-cadherin in prostate cancer bone metastasis. Prostate Cancer Foundation Annual Scientific Retreat (PCF) Sept 2009, Incline Village, NV None(None):None, 2009. PMID: None.
62. Heymach JV, Jonasch E, Wang X, Du DZ, Yan S, Xu L, Herynk MH, McKee KS, Tran HT, Tannir NM, Zurita AJ. A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 27(15S):None, 2009. PMID: None.
63. Zurita AJ, Liu G, Hutson T, Kozloff M, Shore N, Wilding G, Logothetis CJ, Chen I, Chow Maneval E, George D. Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC). 45th Annual Meeting of the American Society of Clinical Oncology (ASCO); Poster (#5166), None(None):None, 2009. PMID: None.
64. Zurita AJ, Wu HK, Lin E, Kulke M, Tye L, Bello CL, DePrimo SE, McKee KS, Heymach JV. Sunitinib (SU) affects specific peripheral blood mononuclear cell subpopulations (PBMC) and circulating endothelial cells (CEC) in patients (pts) with neuroendocrine tumors (NET): correlation with plasma proteins and pharmacokinetics. 2009 Annual AACR Meeting (#LB-284) None(None):None, 2009. PMID: None.
65. Wu HK, Jonasch E, Wood C, Tannir NM, Matin S, McKee KS, Heymach JV, Zurita AJ. Circulating endothelial cells (CEC) and progenitors (CEP) and VEGFR-1-expressing monocytes as biomarkers for patients (pts) with renal cell carcinoma (RCC). 2009 Annual AACR Meeting (#LB-268) None(None):None, 2009. PMID: None.
66. George DJ, Liu G, Wilding G, Hutson TE, Chen I, Chow Maneval E, Logothetis C, Zurita AJ. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refactory prostate cancer (mHRPC)-preliminary results. J Clin Oncol 26(None):None, 2008. PMID: None.
67. Zurita AJ, Ward JF, Araujo JC, Pettaway CA, Pisters LL, Dieringer P, Troncoso P, Logothetis CJ. Presurgical sunitinib malate and androgen ablation in patients with localized prostate cancer at high risk for recurrence. J Clin Oncol 26(None):None, 2008. PMID: None.
68. Li ZG, Navone N, Yang J, Liu J, Mathew P, Starbuck M, Zurita A, Sikes C, Multani A, Efstathiou E, Lopez A, Wang J, Fanning T, Prieto V, Kundra V, Troncoso P, Raymond A, Lin SH, Vazquez E. Androgen receptor-negative human prostate cancer cells induce osteogenesis through FGF9-mediated mechanisms. 2008 Annual AACR Meeting (#1612) None(None):None, 2008. PMID: None.
69. Mancuso P, Antoniotti P, Quarna J, Calleri A, Rabascio C, Tacchetti C, Braidotti P, Wu HK, Zurita A, Saronni L, Cheng J, Shalinsky D, Heymach J, Bertolini F. Molecular, electron-microscopic, inter-laboratory and clinical validation of a novel standardized flow cytometric method for the enumeration of circulating endothelial cells and progenitors. 2008 Annual AACR Meeting (#5855) None(None):None, 2008. PMID: None.
70. Zurita A, Jonasch E, Du D, Yan S, Wang X, Xu L, Herynk M, McKee K, Tran H, Tannir N, Heymach J. Cytokine and angiogenic factor (CAF) profiling for prediction of outcome to first line sorafenib (SR) versus SR plus low-dose interferon-{alpha} (IFN{alpha}) in patients with advanced renal cell carcinoma (mRCC). 2008 Annual AACR Meeting (#LB-218) None(None):None, 2008. PMID: None.
71. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagilaro LC, Corn P, Aparicio AM, Ashe R, Wright JJ, Jonasch E. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. J Clin Oncol 26(None):None, 2008. PMID: None.
72. Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TM, Maneval EC, Chen I, Logothetis CJ. Phase I study of sunitinib in combination with docetaxel and prednisone in metastatic castrate-resistant prostate cancer (CRPC). Department of Defense Prostate Cancer Research Program and Technical Planning Committee for the Innovative Minds in Prostate Cancer Today (IMPaCT); Presentation None(None):None, 2007. PMID: None.
73. Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TM, Maneval EC, Chen I, Logothetis CJ. A phase I/II study of sunitinib in combination with docetaxel (dcx) and prednisone (pdn) in patients with metastatic castrate-resistant prostate cancer (mCRPC). ECCO 14 None(None):None, 2007. PMID: None.
74. Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TW, Chow-Maneval E, Chen I, Logothetis CJ. Distinct patterns of PSA modulation by single-agent sunitinib before combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPCa). J Clin Oncol 25(18S):None, 2007. PMID: None.
75. Zurita AJ, Shore ND, Kozloff MF, Ryan CW, Beer TW, Chow-Maneval E, Chen I, Logothetis CJ. Phase I study of sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone refractory prostate cancer (mHRPC). Prostate Cancer Symposium ASCO None(None):None, 2007. PMID: None.
76. Zurita A, Wu HK, Kulke M, Tye L, Bello C, PePrimo S, McKee K, Heymach J. Sunitinib affects specific subpopulations of peripheral blood monocytic cells in patients with unresectable neuroendocrine tumor (NET): an 8-color flow cytometry analysis. 2007 AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics (#C162) None(None):None, 2007. PMID: None.
77. Jaalouk DE, Kuniyasu A, Zurita A, Beran M, Arap W, Pasqualini R. Targeting of cell surface receptors in leukemia with ligand-directed pro-apoptotic peptides. 14th Annual SPORE Investigators’ Workshop None(None):None, 2005. PMID: None.
78. Zurita AJ, Hajitou A, Cardó-Vila M, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Preclinical development of an interleukin-11 receptor-targeted pro-apoptotic peptide against advanced prostate cancer. 40th Annual Meeting of the American Society of Clinical Oncology; Proc ASCO None(None):None, 2004. PMID: None.
79. Bover LC, Holbeck S, Scudiero DA, Zurita AJ, Sausville E, Pasqualini R, Arap W. Targeting the NCI 60-cell panel by biopanning and rapid analysis of selective interactive ligands. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics; Poster None(None):None, 2003. PMID: None.
80. Zurita AJ, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. A ligand peptide with potential for targeting prostate cancer metastatic to the bone marrow. 94th Annual Meeting of the American Association for Cancer Research; Proc AACR 44(None):None, 2003. PMID: None.

Book Chapters

1. Ro J, Divatia M, Guo CC, Ozcan A. Renal Cell Carcinoma: Oncologist Point of View. In: Kidney Cancer: Recent Advances in Surgical and Molecular Pathology. 1. Springer International Publishing, 21-29, 2019.
2. Heymach JV, Zurita-Saavedra A, Kopetz S, Cascone T, Nilsson M. 17 Tumor angiogenesis. In: In Holland-Frei Cancer Medicine. 9th. Wiley-Blackwell, None, 2017.
3. Zurita AJ, Ward JF, Kim J. Targeted Therapy in Prostate Cancer. In: Targeted Therapy in Cancer. None. The Humana Press, USA, 289-304, 2008.
4. Zurita AJ, Wu HK, Heymach JV. Blood-Based Biomarkers for VEGF inhibitors. In: Antiangiogenic Cancer Therapy. None. Taylor and Francis Group, LLC Authors, 517-31, 2007.
5. Zurita AJ, Arap W, Pasqualini R. Molecular Characterization of the Endothelium: A Phage Display Perspective The Endothelium: a phage display perspective the endothelium. In: A Comprehensive Reference: The Endothelial Cell as Imput-Ouptut Device/Output/Proteome. None. Marcel Dekker, Inc, 898-908, 2007.

Letters to the Editor

1. Zurita Saavedra AJ, Navarro Garcia M, Español I, Fernández Ortega A. UFT-induced haemolytic anaemia. Cancer Chemother Pharmacol 47: 280-81, 2001.